Pharmaceutical California, USA-based Onyx Pharmaceuticals (Nasdaq: ONXX) says it has completed the New Drug Application submission to the Food and Drug Administration under the accelerated approval process for carfilzomib, a next generation proteasome inhibitor, for the potential treatment of patients with relapsed and refractory multiple myeloma. In addition, Onyx has requested priority review of the application, which reduces the time the FDA takes to review a new drug application. 29 September 2011